Method for constructing immunodeficient Chinese hamster by knocking out Prkdc gene based on CRISPR / Cas9 technology

Through CRISPR/Cas9 technology, sgRNA specifically targeting the Prkdc gene was designed, and microinjected into the fertilized egg of Chinese gophers with Cas9 protein, solving the problem of lack of efficient gene editing in the existing technology, and successfully constructing a stable Chinese gopher immune deficiency model, broadening its application in biomedical research.

CN120442627APending Publication Date: 2025-08-08SHANXI MEDICAL UNIV
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
CN202510590751.1
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Filing Date
2025-05-08
Publication Date
2025-08-08

AI Technical Summary

Technical Problem

The lack of efficient and precise gene editing methods in the prior art to construct an immunodeficiency model of Chinese gophers limits its application in biomedical research, especially in oncology research.

Method used

CRISPR/Cas9 technology was used to design sgRNA specifically targeting the Prkdc gene, and knock out the Cas9 protein, microinjected into the fertilized egg and reproduced in surrogate mother mice, and a stable Prkdc knockout Chinese gopher strain was obtained.

Benefits of technology

It has achieved high-precision, simple and fast Prkdc gene knockout, successfully prepared the Chinese gopher immunodeficiency animal model, enriched the resources of immunodeficiency animal model, and provided new tools for the study of tumor disease pathogenesis.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN120442627A_ABST
    Figure CN120442627A_ABST
Patent Text Reader

Abstract

The invention relates to the technical field of transgenosis, in particular to a method for knockout of a Prkdc gene based on a CRISPR / Cas9 technology to construct an immunodeficient Chinese hamster. According to the invention, the CDS region of the Chinese hamster Prkdc gene is knocked out by utilizing a CRISPR / Cas9 technology, gRNA for targeted knockout of the Chinese hamster Prkdc gene is provided, and the application of a gene editing technology in the Chinese hamster is widened. The method for constructing the Prkdc gene knockout Chinese hamster animal model by using the CRISPR / Cas9 system has the advantages of high accuracy, simplicity, feasibility and short period, and provides service for research on immunodeficiency animal models and pathogenesis of human tumor diseases. The invention detects that the expression of T and B lymphocytes is reduced, which indicates that the Chinese hamster immunodeficiency animal model is successfully prepared. The application range of the Chinese hamster is widened, and a new species is provided for an immunodeficiency animal model.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The present invention relates to the field of transgenic technology, and in particular to a method for knocking out the Prkdc gene based on CRISPR / Cas9 technology to construct immunodeficient Chinese hamsters. Background Art

[0002] Gene editing technology involves the targeted modification of genomic DNA using endonucleases, enabling the deletion or replacement of specific DNA bases. Currently, three commonly used gene editing tools are zinc finger nucleases (ZFNs), transcription activator-like effector nucleases (TALENs), and the CRISPR / Cas9 system. CRISPR / Cas9 technology requires only the combined action of guide RNA (gRNA) and the Cas9 nuclease to edit the target sequence, offering advantages such as simplicity, high specificity, and high cleavage efficiency. Soon after its development, researchers successfully achieved gene editing in mammalian cells and subsequently applied it to a variety of organisms, resulting in the generation of a variety of genetically modified organisms. Currently, CRISPR / Cas9 technology is widely used in oncology research. By injecting Cas9 protein and gRNA sequences into fertilized eggs to create mutant animal models targeting key genes in tumor development, these models are used to study disease pathogenesis and provide new model resources for biomedical research. In addition, this technology has been used to construct gene knockout models in a variety of species, providing an important means for studying the functions of specific genes and disease mechanisms.

[0003] Immunodeficient animals are crucial model animals in preclinical research, widely used in biomedicine, particularly in oncology, for their ability to tolerate xenografts. Nude mice, characterized by rapid subcutaneous tumor formation due to a Foxn1 gene mutation that results in thymic hypoplasia and hairlessness, are currently widely used. Furthermore, a variety of immunodeficient animals can tolerate xenografts. For example, severely immunodeficient NSG mice can tolerate human xenografts without developing graft-versus-host disease, offering significant advantages in transplanting xenogeneic cells, tissues, or organs.

[0004] The Prkdc gene encodes the catalytic subunit of DNA-dependent protein kinase (DNA-PKcs), which plays an important role in DNA damage repair in mammalian cells. DNA-PKcs, along with the Ku70 / Ku80 heterodimeric protein, participates in the repair and recombination of DNA double-strand breaks. DNA-PKcs is also involved in lymphocyte development, antibody V(D)J recombination, assembly of immunoglobulin and T cell receptor genes, and the establishment of the central immune tolerance system. CRISPR / Cas9, a novel gene-editing technology, enables genome editing and boasts advantages such as high efficiency, flexibility, precision, species-wide applicability, and cost-effectiveness. This technology can be used to achieve gene deletion, base substitution, and sequence insertion. Currently, a variety of immunodeficient animal models have been constructed by knocking out the Prkdc gene, such as mice, rats, pigs, rabbits, and zebrafish, providing important tools for research in oncology, pharmacology, and immunology.

[0005] The Prkdc gene encodes the catalytic subunit of DNA-dependent protein kinase (DNA-PKcs), which is involved in lymphocyte development, antibody V(D)J recombination, immunoglobulin and T cell receptor gene assembly, and the establishment of the central immune tolerance system. It also plays a crucial role in maintaining telomere length and stability, and is closely linked to the maintenance of chromosomal stability. DNA-PKcs can also be used to understand the occurrence, progression, and treatment outcomes of different tumor types. It can also predict the results of radiotherapy, chemotherapy, and immune checkpoint inhibitors. As a key immune-related gene, it is of great research value. Therefore, Prkdc gene deletion in animals leads to severe combined immune deficiency (SCID). Prkdc deficiency in mice prevents V(D)J rearrangement of the TCR and BCR, which in turn impairs T and B cell maturation and results in complete loss of autologous T and B cell expression. Developing Prkdc gene deletions in different species will not only enrich the resource of immunodeficiency animal models but also provide new, more targeted tools for tumor immunity.

[0006] The Chinese hamster, a unique rodent species unique to my country, has been introduced into laboratories for medical research. Its high sensitivity to certain bacteria, viruses, and protozoa has gradually been recognized, leading to increasing attention in the medical community and a significant role in biomedical research. The Chinese hamster, with its highly similar anatomy, physiology, immunology, and pathology to humans, plays a crucial role in research fields such as medicine, genetics, and biopharmaceuticals. With increasing research, more and more biological characteristics of the Chinese hamster have been discovered, and numerous animal models of Chinese hamster diseases have been established. While the Chinese hamster is widely used in molecular biology and is an indispensable laboratory animal in medical research, its application is far less than that of more commonly used laboratory animals such as mice and rats. Furthermore, data on microinjection of fertilized Chinese hamster eggs is scarce, and as an emerging laboratory animal strain, the stability of genome editing in this species remains to be determined. Therefore, the development of new immunodeficient Chinese hamster models is urgently needed to expand my country's laboratory animal resources and provide researchers with a wider range of options. Summary of the Invention

[0007] The purpose of the present invention is to provide a method for constructing immunodeficient Chinese hamsters by knocking out the Prkdc gene based on CRISPR / Cas9 technology, so as to solve the problems existing in the above-mentioned prior art.

[0008] To achieve the above object, the present invention provides the following solutions:

[0009] The present invention provides an sgRNA for editing the Prkdc gene, wherein the nucleotide sequence of the sgRNA is shown in any one of SEQ ID NO.2-SEQ ID NO.5.

[0010] The present invention provides the use of the above-mentioned sgRNA in preparing a product for knocking out the Chinese hamster Prkdc gene.

[0011] Preferably, the product comprises a reagent or a kit.

[0012] The present invention provides a product for knocking out the Chinese hamster Prkdc gene, which includes the above-mentioned sgRNA.

[0013] Preferably, the product comprises a reagent or a kit.

[0014] The present invention provides the use of the above-mentioned sgRNA or the above-mentioned product in constructing a Prkdc gene knockout Chinese hamster animal model.

[0015] The present invention provides a method for constructing a Prkdc gene knockout Chinese hamster animal model, comprising the following steps:

[0016] After microinjecting the injection solution into the fertilized egg, the resulting fertilized egg was transplanted into a surrogate mother mouse to obtain offspring, identify the genotype, and obtain F0 generation positive Chinese hamsters; the injection solution includes Cas9 mRNA and the above-mentioned sgRNA;

[0017] mating the F0 generation positive Chinese hamster with a wild-type Chinese hamster to obtain an F1 generation Chinese hamster, identifying the genotype, and obtaining an F1 generation heterozygous Chinese hamster;

[0018] The male and female F1 generation heterozygous Chinese hamsters are mated to obtain F2 generation Chinese hamsters, and the genotypes are identified to obtain F2 generation homozygous Chinese hamsters, thereby obtaining the Prkdc gene knockout Chinese hamster animal model.

[0019] Preferably, in the injection solution, the mass ratio of the sgRNA to the Cas9 mRNA is 1:2.

[0020] Preferably, the dosage of the injection is 1 pL / pill.

[0021] The present invention provides an application of a Prkdc gene knockout Chinese hamster animal model obtained by the above-mentioned construction method in studying the pathogenesis of immunodeficiency and / or tumor diseases.

[0022] The present invention discloses the following technical effects:

[0023] The present invention utilizes CRISPR / Cas9 technology to design sgRNA that specifically targets the Prkdc gene, and combines it with Cas9 protein to perform knockout, thereby obtaining a stably propagated Prkdc gene knockout Chinese hamster strain. The present invention utilizes CRISPR / Cas9 technology to knock out the CDS region of the Chinese hamster Prkdc gene, providing a gRNA for targeted knockout of the Chinese hamster Prkdc gene, and broadening the application of gene editing technology in Chinese hamsters. The present invention uses the CRISPR / Cas9 system to construct a Prkdc gene knockout Chinese hamster animal model with the advantages of high accuracy, simplicity, and a short cycle, and provides services for studying immunodeficiency animal models and the pathogenesis of human tumor diseases. At the same time, the present invention detected reduced expression of T and B lymphocytes by flow cytometry, indicating that an immunodeficiency animal model of the Chinese hamster was successfully prepared. The present invention broadens the application of the Chinese hamster and provides a new species for immunodeficiency animal models. BRIEF DESCRIPTION OF THE DRAWINGS

[0024] In order to more clearly illustrate the embodiments of the present invention or the technical solutions in the prior art, the following briefly introduces the drawings required for use in the embodiments. Obviously, the drawings described below are only some embodiments of the present invention. For ordinary technicians in this field, other drawings can be obtained based on these drawings without paying any creative work.

[0025] Figure 1 It is a schematic diagram of the technical solution of the present invention;

[0026] Figure 2 for the Prkdc-gRNA1, Prkdc-gRNA2, Prkdc-gRNA3, and Prkdc-gRNA4 sequence sites;

[0027] Figure 3 The following are the genotype identification results of F0 generation mice; A is the F0 generation born by surrogate mice; B is the agarose gel electrophoresis of the Prkdc gene DNA sequence of the F0 generation; C is the Sanger sequencing of the F0-2 / F0-3 Prkdc gene; D is the F0-2 / F0-3 Prkdc gene knockout sequence;

[0028] Figure 4 A is the genotype identification of the F0-3-F2 generation; A is the homozygous breeding mode of the F0-3-F2 generation; B is the agarose gel electrophoresis of the Prkdc gene DNA sequence of the F0-3-F2 generation; C is the Prkdc gene knockout sequence of F2-2 and F2-9;

[0029] Figure 5 This is the off-target gene site of Prkdc-gRNA4;

[0030] Figure 6 is the off-target identification result; Marker is the standard protein, WT is the wild-type Chinese hamster, F0-2 is the F0-2 Chinese hamster, F0-3 is the F0-3 Chinese hamster, and Water is water;

[0031] Figure 7 The expression levels of Prkdc mRNA in major organs of Prkdc gene-knockout Chinese hamsters; n = 6; * indicates P < 0.05 compared with the control group; ** indicates P < 0.01; *** indicates P < 0.001;

[0032] Figure 8 The expression level of DNA-PKcs in the heart of Prkdc gene-knockout Chinese hamsters; IHC staining, n = 6; * indicates comparison with the control group, *** indicates P < 0.001;

[0033] Figure 9 The content of T and B lymphocytes in PBMC of Prkdc gene knockout Chinese hamsters;

[0034] Figure 10This is the growth curve of Prkdc gene knockout Chinese hamsters; WT♂ is the wild-type male Chinese hamster, WT♀ is the wild-type female Chinese hamster, Prkdc KO♂ is the Prkdc gene knockout male Chinese hamster, and Prkdc KO♀ is the Prkdc gene knockout female Chinese hamster;

[0035] Figure 11 The figure shows the appearance of Prkdc gene knockout Chinese hamsters; WT♂ is the wild-type male Chinese hamster, WT♀ is the wild-type female Chinese hamster, Prkdc KO♂ is the Prkdc gene knockout male Chinese hamster, and Prkdc KO♀ is the Prkdc gene knockout female Chinese hamster.

[0036] Figure 12 H&E staining of the main organs of Prkdc gene knockout Chinese hamsters. DETAILED DESCRIPTION

[0037] Various exemplary embodiments of the present invention will now be described in detail. This detailed description should not be considered as limiting the present invention, but rather as a more detailed description of certain aspects, features, and embodiments of the present invention.

[0038] It should be understood that the terms described herein are intended only to describe particular embodiments and are not intended to limit the present invention. In addition, for numerical ranges herein, it should be understood that each intermediate value between the upper and lower limits of the range is also specifically disclosed. The intermediate value within any stated value or stated range, and each smaller range between any other stated value or intermediate value within the stated range, is also encompassed within the present invention. The upper and lower limits of these smaller ranges may be independently included or excluded within the scope.

[0039] Unless otherwise indicated, all technical and scientific terms used herein have the same meaning as commonly understood by those skilled in the art. Although only preferred methods and materials are described herein, any methods and materials similar or equivalent to those described herein may also be used in the practice or testing of the present invention. All documents mentioned in this specification are incorporated by reference to disclose and describe the methods and / or materials associated with the documents. In the event of any conflict with any incorporated document, the contents of this specification shall prevail.

[0040] It will be apparent to those skilled in the art that various modifications and variations may be made to the specific embodiments described herein without departing from the scope or spirit of the invention. Other embodiments will be apparent to those skilled in the art from the description of the invention. The description and examples are intended to be exemplary only.

[0041] The words “include,” “including,” “have,” “contain,” etc. used in this document are open-ended terms, meaning including but not limited to.

[0042] The schematic diagram of the technical solution of the present invention is as follows Figure 1 The present invention is specifically described through the following embodiments.

[0043] Example 1 Prkdc-gRNA design

[0044] This example is based on the NCBI database to clarify the information of the Chinese hamster Prkdc gene. The transcripts containing all coding regions are used as the research objects. The gRNA sequences with high cutting efficiency and specificity are screened by the CRISPOR platform system. The details are as follows:

[0045] Based on the annotation information of the NCBI database (Gene ID: 100770748), it was determined that the Chinese hamster Prkdc gene is located on chromosome 4, including transcripts Prkdc-201 and Prkdc-202, both of which encode proteins. The present invention takes the Prkdc-202 (TranslationID: ENSCGRP00001003289.1) transcript as the research object, and this transcript has a total of 86 exons. To ensure that gene editing can silence two transcripts at the same time, the CDS region of their shared Exon1 (a total of 154bp, SEQ ID NO.1) was systematically analyzed through the CRISPOR platform, and 22 candidate Prkdc-gRNAs (13 targeting the leading chain and 9 targeting the lagging chain) were found. Based on the cutting efficiency score and genome-wide off-target risk prediction, 4 Prkdc-gRNAs were screened out (Table 1, Figure 2 ), any one of which, if it has cleavage activity, can lead to sequence frameshifting, thereby achieving the purpose of shearing the gene. In addition, the present invention also designed PCR primers for identifying the shearing efficiency of Prkdc-gRNA (Table 2).

[0046] The nucleotide sequence of the CDS region of Exon 1 is shown in SEQ ID NO. 1, specifically:

[0047] 5'-ATGGAGGACGCAGGAGCCGGCATCCGCGGATGGCTACTGCAGCTGCAGGAGTTC CTGTCGGCGGCGGACCGCTGCAGCGCTGCCGGCGCCAGTTACCAGCTGATCCGTGGCCT GGGGCAGGAGTGCGTGCTGAGCACCAGCTCCGCTGTGCTGG-3'.

[0048] Table 1 Sequence information and scores of 4 highly efficient Prkdc-gRNAs

[0049] gRNA name gRNA sequence (5'-3') Off-target scoring Cutting score Prkdc-gRNA1 GACGCAGGAGCCGGCATCCG(SEQ ID NO.2) 91 78 Prkdc-gRNA2 CAGGAGCCGGCATCCGCGGA(SEQ ID NO.3) 94 69 Prkdc-gRNA3 GCTGCAGGAGTTCCTGTCGG(SEQ ID NO.4) 88 84 Prkdc-gRNA4 ACCAGCTGATCCGTGGCCTG(SEQ ID NO.5) 86 73

[0050] Table 2 PrkdcgRNA shear identification primer sequences

[0051]

[0052] Example 2 PrkdcgRNA Synthesis

[0053] This example uses a PCR-in vitro transcription method to obtain a complete gRNA sequence. According to the gRNA sequence, an upstream primer containing a T7 promoter, a crRNA with targeting specificity, and homology to the Scaffold region was designed, totaling 56-58nt (containing a T7 promoter sequence, and two "G" bases to enhance in vitro transcription). The complete gRNA template was obtained after PCR using the Guide-it sgRNA In Vitro Transcription Components v2 kit. The PCR amplification product in the above steps was used as a template, and in vitro transcription was performed using the Guide-it sgRNA In Vitro Transcription Components v2 kit. The Guide-it IVT RNAClean-Up kit was used for 4 gRNA purification, as follows:

[0054] The complete Prkdc-gRNA sequence was obtained by PCR-in vitro transcription method. According to the Prkdc-gRNA sequence, an upstream primer containing a T7 promoter, a crRNA with targeting specificity, and homology to the Scaffold region was designed, totaling 56-58nt (including the T7 promoter sequence, and two "G" bases to enhance in vitro transcription). The upstream of the T7 promoter contains 4 additional nt of "CCTC", 17nt of the T7 promoter, 0-2nt of the base "G", 20nt of crRNA, and 15nt of the Scaffold homologous fragment (Table 3). The complete Prkdc-gRNA template was obtained after PCR using Guide-it sgRNA In Vitro Transcription Components v2 (Cat.No.632637) (PCR reaction system and procedure are shown in Tables 4 and 5). The downstream primer Guide-it Scaffold Template can target the 3' end of the Scaffold and is premixed with the Scaffold template.

[0055] Table 3 Upstream primers for Prkdc-gRNA template synthesis

[0056]

[0057] Note: The double-underlined part is the T7 promoter DNA sequence, the single-underlined part is one base "G" or two bases "G", the bold part is the gRNA DNA sequence (crRNA), and the emphasized part is the Scaffold homologous fragment DNA sequence.

[0058] Table 4 Prkdc-gRNA PCR reaction system

[0059] Reagents Dosage (μL) PrimeSTARMaxPremix(2×) 12.5 Guide-itScaffoldTemplate 1 Yourforwardprimer (10μM) 0.5 RNaseFreeWater 11 Total 25

[0060] Table 5 PCR reaction program

[0061]

[0062]

[0063] Example 3 Cas9 / Prkdc-gRNA microinjection

[0064] In this example, 4-6 week old female Chinese hamsters were selected for superovulation to obtain fertilized eggs. Cas9 mRNA and gRNA were microinjected into the pronuclei of the fertilized Chinese hamster eggs, which were then transplanted into surrogate female mice. The surrogate female mice gave birth 19-21 days after the operation, as follows:

[0065] 1. Obtaining Chinese Hamster Fertilized Eggs

[0066] Female Chinese hamsters aged 4-6 weeks and weighing approximately 18 g were selected (purchased from: Experimental Animal Center of Shanxi Medical University, production license: SCXK [Jin] 2024-0004, breeding environment: Experimental Animal Center of Shanxi Medical University, use license: SYXK [Jin] 2024-0007), and male Chinese hamsters aged 10-12 weeks and weighing approximately 30 g were selected (purchased from: Experimental Animal Center of Shanxi Medical University, production license: SCXK [Jin] 2024-0004, breeding environment: Experimental Animal Center of Shanxi Medical University, use license: SYXK [Jin] 2024-0007) and mated with the above-mentioned female Chinese hamsters to obtain fertilized eggs.

[0067] (1) Superovulation: Female Chinese hamsters used for oocyte retrieval were injected with 0.15 mL of PMSG (15 IU) at 16:00 on the first day of the experiment and 0.15 mL of PMSG (15 IU) at 9:00 on the fourth day. They were then injected with 0.15 mL of LHRH (0.6 μg) at 16:00 and then placed in the same cage with male Chinese hamsters.

[0068] (2) Acquisition of fertilized eggs:

[0069] ① Collect fertilized eggs 0.5 days post coitum (dpc);

[0070] ② Kill the female Chinese heron by cervical dislocation. Spray the abdomen with alcohol to moisten it. Use ophthalmic scissors to open the abdominal cavity. Locate the uterus, fallopian tube, and ovary. Trim away excess fat around the uterus. Cut open the ovary at the junction with the fallopian tube. Cut open the uterine horn at the junction with the fallopian tube. Remove the fallopian tube and immerse it in D-PBS.

[0071] ③ Under a stereomicroscope, remove excess fat in D-PBS with ophthalmic forceps, transfer to M2 medium containing 1200 U / mL hyaluronidase (HA), find the dilated part of the oviduct, and poke a hole in the dilated part with a 1 mL syringe needle. Eggs should be seen flowing out of the hole.

[0072] ④ Digest in HA for 3-5 minutes to remove the cumulus cells around the eggs, use an egg transfer needle to aspirate into M2 medium and wash until there are no cumulus cells around them, select the fertilized eggs with two pronuclei, transfer them into M2 medium that has been pre-equilibrated in a 37℃ 5% CO2 incubator for 30 minutes, and place them in a 37℃ 5% CO2 incubator for subsequent microinjection. After the fertilized eggs are exposed from the oviduct, all operations require red light irradiation.

[0073] 2. Microinjection of Chinese hamster fertilized eggs

[0074] The egg-holding needle and injection needle required for microinjection were drawn on a P-97 needle puller, and the egg-holding needle necking and the angles of the egg-holding needle and injection needle were completed on the MF-900.

[0075] (1) Preparation of egg-holding needle:

[0076] ① Set the HEAT on the P-97 needle puller to 720, PULL to 110, VEL to 55, and TIME to 75.5;

[0077] ② Fix the 1×90mm siliconized capillary glass tube (G-1) to the needle puller and press "PUSH" to break the glass tube;

[0078] ③ Remove the pulled glass tube from the needle puller and use a small grinding wheel to break off the needle tip about 1.3 cm away from the needle tip, so that the outer diameter of the tube mouth is 80-120 μm;

[0079] ④ Clamp the glass tube onto the micro-calciner and lower the glass needle tip close to the glass ball on the platinum wire, but do not touch the glass ball surface;

[0080] ⑤ Adjust the heating temperature of the platinum wire on the calciner to 50-60℃, press the pedal to heat the platinum wire, and observe the change in the inner diameter of the glass tube until it shrinks to about 15μm;

[0081] ⑥ Release the foot pedal, rotate the egg holding needle to horizontal, move the glass tube to 100μm above the platinum wire, move the needle tip to 0.5cm to the right of the platinum wire, step on the foot pedal to allow the platinum wire to heat the glass tube, remove the calcined glass needle when the observation angle reaches 20-30°, and the egg holding needle is successfully made.

[0082] (2) Preparation of injection needles:

[0083] ① Set the HEAT on the P-97 needle puller to 759, VEL to 150, and TIME to 200;

[0084] ② Fix the 1×90mm siliconized capillary glass tube with glass fiber (GD-1) to the needle puller and press "PUSH" to break the glass tube;

[0085] ③ Remove the pulled glass tube from the needle puller, clamp the glass tube onto the micro-calcining instrument, keep the glass tube horizontal, move the glass tube to a distance of 100μm above the platinum wire, and place the glass tube and the platinum wire at the same vertical plane with an outer diameter of 100μm. Press the foot pedal to allow the platinum wire to heat the glass tube. When the observation angle reaches 20-30°, remove the calcined glass needle. The injection needle is then successfully made and can be used for microinjection.

[0086] (3) Microinjection operation:

[0087] ① Assemble the egg holding needle and injection needle, and adjust the injection needle flow rate;

[0088] ② Remove the fertilized eggs cultured in M2 medium and transfer them into injection chambers (add a drop of M2 medium to the 35mm culture medium cover and completely cover with mineral oil) in groups of 30.

[0089] ③ Under a 40× objective lens, use an egg-holding needle to suck the fertilized egg and stick it to the egg-holding needle tip, find the male and female pronuclei, move the fertilized egg with the injection needle, adjust it to the same plane as the injection needle, and poke the injection needle into the pronucleus of the fertilized egg. When the pronucleus is obviously swollen, change to another pronucleus and perform the same operation (the injection needle should be withdrawn quickly); the injection solution is a mixture of Cas9 mRNA and Prkdc-gRNA, the concentration of Cas9 mRNA in the mixture is 20 ng / μL, the concentration of Prkdc-gRNA is 10 ng / μL, and the injection volume of the injection solution is 1 pL / fertilized egg; Cas9 mRNA was purchased from ThermoFisher (Cat. No.: A29378); the nucleotide sequence of Prkdc-gRNA is shown in SEQ ID NO.2-5;

[0090] ④ After all fertilized eggs are injected, they are transferred into M2 culture medium in a 37°C, 5% CO2 incubator and cultured for 30 minutes before transplantation.

[0091] 3. Chinese Hamster Fertilized Egg Transplantation

[0092] (1) Transfer the fertilized egg cultured in a 37°C, 5% CO2 incubator into a new M2 medium. Use a transplant tube to draw out a 1 cm section of M2 medium, aspirate a small bubble, and then aspirate another small section of M2 medium. Repeat this process until the siphon effect is reduced and the inflow and outflow of liquid can be well controlled.

[0093] (2) Then aspirate the embryo into the transfer tube (with as little M2 culture medium as possible) and inhale a small bubble at the end of the transfer tube;

[0094] (3) 0.5 dpc Chinese hamsters used for surrogate pregnancy were anesthetized with tribromoethanol anesthetic;

[0095] (4) Spray the fur between the legs on the back near the spine with 75% ethanol, and use microtweezers and scissors to straighten the fur in the middle so that a clear line of skin can be seen;

[0096] (5) Make a small incision of about 1 cm at the height of the thigh root, insert the ophthalmic scissors about 2 cm between the skin and muscle layer on the left side, and stretch the scissors to tear the mucosa;

[0097] (6) Slide the skin to find the white fat pad or orange ovary through the body wall. Use No. 5 ophthalmic forceps to lift the body wall, make a small cut above the ovary, and perform blunt separation with forceps or scissors (opening about 1 cm). Use blunt forceps to grasp the fat pad and pull out the attached left ovary, fallopian tube, and uterus.

[0098] (7) Use hemostatic clips to clamp the fat pad and allow it to droop along the mid-dorsum to expose the ovaries, fallopian tubes, and uterus;

[0099] (8) Find the fimbria of the fallopian tube under a microscope and adjust the position of the female mouse and the fallopian tube to make it easier to insert the transplant tube into the fallopian tube;

[0100] (9) Avoid the large blood vessels on the ovarian sac and tear a small hole in the ovarian sac above the fimbria of the fallopian tube with two No. 5 ophthalmic forceps. Clamp the fimbria with No. 5 ophthalmic forceps and insert the transplant tube into the fimbria of the fallopian tube. Then blow the embryo and air bubbles into the ampulla of the fallopian tube (if air bubbles are seen in the fallopian tube, it means that the transplant has been successful);

[0101] (10) Release the fat clamp, grasp the fat pad with blunt forceps, and carefully place the ovaries, fallopian tubes, and uterus back into the body cavity;

[0102] (11) Repeat the above steps to transfer the embryo to the right fallopian tube;

[0103] (12) The surrogate mothers gave birth 19-21 days after the operation.

[0104] Example 4 Identification of Prkdc gene knockout Chinese hamsters in the F0 generation

[0105] In this example, genomic DNA from the tail of the F0 generation of mice was extracted and PCR amplified using primers identifying the Prkdc gene. The amplified product was subjected to Sanger sequencing to analyze whether the Prkdc gene sequence had changed, as follows:

[0106] 234 fertilized eggs were microinjected with Prkdc-gRNA1 / Prkdc-gRNA2 / Prkdc-gRNA3 / Prkdc-gRNA4, resulting in 17 pregnancies, 5 of which gave birth to 9 pups (Table 6). Among the F0 generation, F0-1 was microinjected with Prkdc-gRNA1; F0-2 / 3 were microinjected with Prkdc-gRNA4; F0-4 / 5 were microinjected with Prkdc-gRNA3; F0-6-F0-9 were microinjected with Prkdc-gRNA4, and unborn offspring were microinjected with Prkdc-gRNA2 (Table 7). Genomic DNA was extracted from the mouse tail and the Prkdc gene was identified. It was found that the amplified products of the two pups F0-2 and F0-3 of Prkdc-gRNA4 were smaller than those of the wild-type (WT). Sanger sequencing revealed that a 37nt deletion (Δ37) occurred in the Prkdc-gRNA4 targeting site (the fourth base upstream of PAM), resulting in a frameshift mutation. The allele type was a heterozygous mutation (Prkdc Δ37 / + ); the F0-3 cleavage site shifts to the third base upstream of PAM, resulting in a 7nt deletion (Δ7), which is also a heterozygous mutation (Prkdc Δ7 / + )( Figure 3 The remaining seven F0 individuals (77.8%) were found to have no Prkdc gene sequence changes (Table 7). Therefore, the successful construction of the Prkdc knockout hamster was confirmed at the DNA level.

[0107] Table 6 Fertility of surrogate mice

[0108] Surrogate mouse number Number of fertilized eggs transplanted Number of litters (children) 1 10 1 2 9 - 3 17 - 4 14 - 5 8 2 6 15 - 7 13 - 8 19 - 9 14 - 10 12 - 11 10 2 12 12 - 13 9 - 14 10 - 15 17 - 16 30 3 17 15 1

[0109] Table 7 Prkdc gene knockout in F0 generation Chinese hamsters

[0110] <![CDATA[F0-]]> <![CDATA[WT / Prkdc - / + ]]> ♀ / ♂ 1 WT ♂ 2 <![CDATA[Prkdc - / + ]]> ♀ 3 <![CDATA[Prkdc - / + ]]> ♂ 4 WT ♀ 5 WT ♀ 6 WT ♂ 7 WT ♀ 8 WT ♂ 9 WT ♀

[0111] Example 5 Identification of homozygous Prkdc gene knockout Chinese hamsters

[0112] In this example, positive Chinese hamsters identified as knockout were mated with wild-type Chinese hamsters to obtain F1 generations. Knockout mice were screened out in the F1 generations, and the F1 generation knockout mice were randomly mated to obtain homozygotes. The homozygotes were then bred and mated with each other to obtain stably inherited Prkdc gene knockout Chinese hamster animals, as follows:

[0113] F0-2 and the WT father gave birth to pups, with the first litter having 2 pups, the second litter having 4 pups, the third litter having 4 pups, and the fourth litter having 5 pups. Among the 15 pups born, all of them had the WT phenotype (Table 8).

[0114] The F1 generations 1-6 were born from F0-3 and WT mother. After DNA extraction from rat tail, PCR amplification and Sanger sequencing, it was found that F1-1, F1-3 and F1-5 were heterozygous Prkdc - / + , F1-2, F1-4, F1-6, are WT, among which F1-1 is a male mouse, and F1-3 and F1-5 are female mice (Table 9).

[0115] After F1-1, F1-3, and F1-5 grew to 12 weeks old, F1-1 was mated with F1-3 and F1-5 respectively. After the F2 generation was obtained, the Prkdc gene phenotype was identified. F1-3 and F1-5 each had 5 and 6 pups in their first litter. Among them, F2-3 and F2-9 were homozygous for Prkdc by agarose gel electrophoresis and Sanger sequencing. - / - And one male and one female (Table 10 and Figure 4 ).

[0116] Table 8F0-2-F1 generation information

[0117]

[0118]

[0119] Table 9F0-3-F1 generation information

[0120] <![CDATA[F1]]> female parent Male parent WT / Prkdc- / + ♀ / ♂ 1 WT <![CDATA[F0-3]]> Prkdc- / + ♂ 2 WT <![CDATA[F0-3]]> WT ♀ 3 WT <![CDATA[F0-3]]> Prkdc- / + ♀ 4 WT <![CDATA[F0-3]]> WT ♀ 5 WT <![CDATA[F0-3]]> Prkdc- / + ♀ 6 WT <![CDATA[F0-3]]> WT ♂

[0121] Table 10 Information of Prkdc-7nt knockout F2 generation mice

[0122] <![CDATA[F2]]> female parent Male parent <![CDATA[WT / Prkdc - / + / Prkdc - / - ]]> ♀ / ♂ 1 <![CDATA[F1-3]]> <![CDATA[F1-1]]> <![CDATA[Prkdc - / + ]]> ♂ 2 <![CDATA[F1-3]]> <![CDATA[F1-1]]> WT ♀ 3 <![CDATA[F1-3]]> <![CDATA[F1-1]]> <![CDATA[Prkdc - / - ]]> ♂ 4 <![CDATA[F1-3]]> <![CDATA[F1-1]]> WT ♂ 5 <![CDATA[F1-3]]> <![CDATA[F1-1]]> <![CDATA[Prkdc - / + ]]> ♂ 6 <![CDATA[F1-3]]> <![CDATA[F1-1]]> WT ♂ 7 <![CDATA[F1-3]]> <![CDATA[F1-1]]> Prkdc- / + ♀ 8 <![CDATA[F1-3]]> <![CDATA[F1-1]]> WT ♂ 9 <![CDATA[F1-3]]> <![CDATA[F1-1]]> <![CDATA[Prkdc - / - ]]> ♀ 10 <![CDATA[F1-3]]> <![CDATA[F1-1]]> <![CDATA[Prkdc - / + ]]> ♂ 11 <![CDATA[F1-3]]> <![CDATA[F1-1]]> <![CDATA[Prkdc - / + ]]> ♂

[0123] Example 6 Off-target analysis of Prkdc gene knockout in Chinese hamsters

[0124] The interaction between Cas9 and DNA is first mediated by the recognition and binding of the PAM site. At the same time, the binding between crRNA and the potential target editing sequence undergoes a directed reaction to form a stable R-loop, which in turn activates the enzymatic activity to break the DNA proximal to the PAM. When the gRNA sequence recognizes a partial mismatch outside the specific sequence instead of the target site, an off-target effect will occur. Researchers have found that the off-target effects of CRISPR / Cas9 are usually gRNA-dependent. In addition to editing the target site, the gRNA can also tolerate up to 5-6 mismatched bases, or cause non-targeted cutting at genomic sites where the gRNA lacks or contains extra bases, resulting in off-target effects.

[0125] In this example, potential off-target sites were screened using the CRISPOR and CCTop (https: / / cctop.cos.uni-heidelberg.de:8043 / ) platforms to identify the top five genes with the highest off-target scores located in exons. Sequences of potential off-target sites were searched using NCBI, and primers were designed for PCR amplification. Agarose gel electrophoresis was then used to identify off-target sites, and Sanger sequencing was used to confirm the informative sequences, as follows:

[0126] After CRISPOR and CCTop prediction, 9 potential off-target sites of Prkdc-gRNA4 were found in the exon region. The five genes with the highest potential off-target possibility of Prkdc-gRNA4, ctc1, LOC113832379, Fam20b, Cacna1b, and Aldh18a1, all had 4 base mismatches. Figure 5 ) primers (Table 11) were designed and then agarose gel electrophoresis and Sanger sequencing were performed. Agarose gel results showed that compared with WT, the size of the PCR amplification products at the five potential off-target sites of Prkdc-gRNA4 in F0-generation knockout mice F0-2 and F0-3 did not change significantly ( Figure 6 Sanger sequencing results showed that compared with WT, the base sequences near the five potential off-target sites of Prkdc-gRNA4 in F0-2 and F0-3 were unchanged ( Figure 6 ).

[0127] Table 11 Off-target site primer sequences

[0128]

[0129] Example 7 RT-qPCR detection of Prkdc gene knockout Chinese hamster mRNA expression level

[0130] In this example, in order to analyze the mRNA expression level of Prkdc gene knockout Chinese hamsters, RNA was extracted from the heart, liver, spleen, lung, kidney, thymus and other major organs of Prkdc gene knockout Chinese hamsters (n=6) and used for RT-qPCR to compare with WT Chinese hamsters (n=6). -△△CT Calculate the relative expression as follows:

[0131] 1. Extraction of Tissue RNA

[0132] (1) Add the tissue to RNAiso Plus (1 mL RNAiso Plus per 50 mg tissue) reagent and crush it using an ultrasonic cell disruptor under ice bath conditions;

[0133] (2) The homogenized sample was placed at room temperature for 5 min to allow the nucleic acid-protein complex to be completely separated;

[0134] (3) Add 0.2 mL of chloroform to every 1 mL of RNAiso Plus, shake vigorously for 15 seconds, and let stand at room temperature for 3 minutes;

[0135] (4) Centrifuge at 4°C, 12,000 rpm for 15 min and collect the supernatant separately. Transfer the colorless aqueous phase to a new 1.5 mL enzyme-free EP tube, typically 400-600 μL.

[0136] (5) Precipitate the RNA in the aqueous phase with isopropanol. Add 0.5 mL of isopropanol per 1 mL of RNAiso Plus or add an amount of isopropanol equal to the supernatant and let it stand at room temperature for 10 min.

[0137] (6) Centrifuge at 4°C, 12,000 rpm for 10 min. Discard the supernatant and retain the precipitate.

[0138] (7) Wash the RNA pellet with 75% ethanol. Add at least 1 mL of 75% ethanol for every 1 mL of RNAiso Plus used. Centrifuge at no more than 7500 rpm at 4°C for 5-10 minutes and discard the supernatant.

[0139] (8) Repeat washing twice;

[0140] (9) Dry the precipitate in a clean bench for 30 min. Dissolve the precipitate with 30-100 μL of sterile enzyme-free water. Use a microplate spectrophotometer to measure RNA purity and concentration. OD 260 / OD 280 It is better to use 1.8-2.1.

[0141] 2. RNA Primer Design

[0142] RT-qPCR primers (Table 12) were designed on the Primer-BLAST online design website (https: / / www.ncbi.nlm.nih.gov / tools / primer-blast / index.cgi?LINK_LOC=BlastHome) to quantify the mRNA expression level of the Prkdc gene in each tissue. The primers were synthesized by Wuhan Saiweier Company.

[0143] Table 12 RT-qPCR primer sequences

[0144]

[0145] 3. RNA Reverse Transcription

[0146] Using PrimeScript TM Perform reverse transcription using the relevant reagents in the RTMaster Mix (Perfect Real Time) kit. Load the sample into a 200 μL centrifuge tube according to the information in Table 13. The reaction procedure is shown in Table 14. After the reverse transcription reaction is complete, add 50 μL of sterile, enzyme-free HO to the reverse transcription reaction system to dilute the reaction product. All operations were performed in an ice bath.

[0147] Table 13 mRNA reverse transcription system

[0148] Reagents volume 5×PrimeScriptTMRTMasterMix 2μL RNASample 500ng <![CDATA[RNaseFreeddH2O]]> Make up to 50 μL

[0149] Table 14 mRNA reverse transcription reaction program

[0150] Temperature (℃) time 37 15min 85 5s 4 10min

[0151] 4. RT-qPCR

[0152] After successful reverse transcription of RNA to cDNA, add each component to the corresponding 8-tube strip according to the sample loading system shown in Table 15. Strictly avoid RNase contamination during the loading process. After loading, replace the optical cap of the 8-tube strip with the corresponding sample tube. Be careful not to stain the cap to prevent it from affecting the quantitative results. The qRT-PCR reaction system is shown in Table 16; the total volume for this process is 20 μL; the internal reference gene is β-actin (or Gapdh).

[0153] Table 15 RT-qPCR reaction system

[0154] Reagents Volume (μL) TBGreen Premix ExTaqTMⅡ(2×) 10 ROXReferenceDye(50×) 0.4 cDNA 2 PCRForwardPrimer (10 μM) 0.8 PCR Reverse Primer (10 μM) 0.8 <![CDATA[ddH2O]]> 6 Total 20

[0155] Table 16 RT-qPCR reaction procedure

[0156]

[0157] Graphpadprism 9.0.0 software was used to analyze the results, and the t-test was used. When P < 0.05, the statistical results were considered to be statistically significant. The results showed that the expression levels of Prkdc mRNA in the liver, spleen, heart, lung, kidney, and thymus of the Prkdc gene knockout Chinese hamsters were significantly decreased ( Figure 7 ).

[0158] Example 8 IHC detection of DNA-PKcs expression level in Prkdc gene knockout Chinese hamsters

[0159] The Prkdc gene encodes a protein called DNA-dependent protein kinase catalytic subunit (DNA-PKcs), which expresses the DNA-PKcs protein. Therefore, the present invention uses immunohistochemistry (IHC) staining to compare the expression of DNA-PKcs in the main organs of Prkdc gene knockout Chinese hamsters with that of WT Chinese hamsters. The specific steps are as follows:

[0160] (1) Fix the tissue in 4% paraformaldehyde for approximately 48 hours and then rinse in running water overnight (12-18 hours);

[0161] (2) 70% ethanol overnight → 80% ethanol 2 hours → 90% ethanol 2 hours → 95% ethanol 2 hours → 100% ethanol I and II for 1 hour each → xylene I and II for 1 hour each;

[0162] (3) Wax I (48-50℃) 1h → Wax II (54-56℃) 1h → Wax III (56-58℃ or 60-62℃) 1h → Place the tissue in the iron embedding mold according to the sectioning requirements, then carefully pour wax III into the embedding mold, carefully cover the plastic embedding box on the iron embedding mold, and finally add a little liquid paraffin and cool it to make the paraffin solid;

[0163] (4) Before slicing, turn on the water bath and heat it to 50-60°C. When slicing, first trim the wax block so that the tissue in the wax block is exposed on the surface. Then place the wax block on the paraffin microtome, adjust the slice thickness to 4 μm, and carefully turn the microtome handle to perform continuous slicing.

[0164] (5) Place the wax strip containing the intact tissue in a 50-60°C water bath. Before placing the slide in the water, remove any bubbles in the water bath to prevent them from floating up due to the heat and sticking to the tissue.

[0165] (6) Place the fully unfolded wax strips on the corresponding numbered slides, 2-3 wax strips per slide, and 5-6 strips per tissue. It is best to keep the direction consistent when scooping the slides for easier observation.

[0166] (7) Place the waxed slide on an iron or copper slide rack and bake the rack in an oven at 60-70°C for 1 hour.

[0167] (8) Xylene I for 15 minutes → Xylene II for 10 minutes → Anhydrous ethanol I and II for 1-2 minutes each → 95% ethanol for 1-2 minutes → 80% ethanol for 1-2 minutes → Gently rinse with tap water for a while;

[0168] (9) Inactivation of endogenous enzymes: After dewaxing, rinse in clean water for a period of time, add 3% H2O2 and soak for 10 minutes, then remove the H2O2 and rinse twice in clean water;

[0169] (10) Antigen retrieval: After adding citric acid buffer, place in a microwave oven and cook on medium heat for 3 minutes, cool to room temperature, and then start cooking again. Repeat three times to completely expose the antigen site.

[0170] (11) Blocking: After cooling to room temperature, discard the citric acid buffer solution, wash twice with clean water, place the slide in a box containing PBS and scrub for 5 minutes, repeat twice, and aspirate the PBS around the tissue; immediately add serum blocking solution (5% BSA) to block nonspecific sites and let it stand at room temperature for 10 minutes;

[0171] (12) Primary antibody incubation: Remove the slide, wipe the serum on the front and back of the slide and around the tissue with absorbent paper, carefully add the primary antibody to the tissue, and after adding the primary antibody, move it into a moisturizing box and incubate it at 4°C overnight;

[0172] (13) Secondary antibody incubation: Wash the slides in PBS three times, 5 min each time. After drying the PBS around the tissue, carefully add the secondary antibody and incubate in a 37°C incubator for 0.5-2 h.

[0173] (14) Add SABC (streptavidin + horseradish enzyme labeled biotin): Take the slide out of the incubator and wash it in PBS three times, 3 minutes each time. After drying the PBS around the tissue, carefully add SABC solution and incubate it in a 37°C incubator for 30 minutes.

[0174] (15) Color development: Wash in PBS three times, 5 min each time, wipe the PBS around the tissue dry, carefully add DAB color developer, develop color at room temperature, and observe under a microscope to control the reaction time;

[0175] (16) Restaining: After the color development is completed, rinse the slide with clean water for a period of time, soak it in hematoxylin for staining, and observe under a microscope to determine the specific staining time;

[0176] (17) Dehydration: After washing in sterile water, place in 70% ethanol for 2-3 min → 80% ethanol for 2-3 min → 90% ethanol for 2-3 min → 95% ethanol for 2-3 min → 100% ethanol I and II for 2-3 min each → xylene I and II for 2-3 min each;

[0177] (18) Sealing: Add an appropriate amount of neutral gum to the slide, and slowly lower the cover slip from one side to complete the sealing process. Avoid the generation of bubbles during the sealing process. After sealing, place the slide in a fume hood to dry.

[0178] Immunohistochemical staining was quantified using Image J software; Graphpadprism 9.0.0 software was used for statistical analysis, using the t-test. P < 0.05 was considered statistically significant. The results showed that DNA-PKcs expression levels were significantly decreased in major organs, including the liver, spleen, heart, lungs, kidneys, and thymus. Figure 8 ).

[0179] Example 9 Flow cytometry detection of T and B lymphocyte expression in Prkdc gene knockout Chinese hamsters

[0180] The present invention detects the expression of T and B lymphocytes in Chinese hamsters with Prkdc gene knockout by flow cytometry. PBMCs are prepared by collecting peripheral blood of Chinese hamsters with Prkdc gene knockout, and CD3 + CD19 - T lymphocytes, CD3 - CD19 + B lymphocytes, the specific steps are as follows:

[0181] CD45 is a unique antigen on the surface of white blood cells, so CD45 is used to mark white blood cells in peripheral blood PBMC. CD3 is a common surface marker antigen for all T lymphocytes, and CD19 is a specific surface marker antigen for B lymphocytes. + CD19 - Marker T lymphocytes, CD3 - CD19 + Marks B lymphocytes.

[0182] PBMCs were prepared by collecting peripheral blood from Prkdc gene knockout Chinese hamsters. CD3 + CD19 - T lymphocytes, CD3 - CD19 + The results showed that Prkdc gene knockout of CD3 in PBMC of Chinese hamsters + CD19 -T lymphocytes, CD3 - CD19 + B lymphocytes were significantly lower than WT ( Figure 9 ).

[0183] Example 10: Appearance of Prkdc gene knockout Chinese hamsters

[0184] This example compares whether Prkdc gene knockout affects the growth and development of Chinese hamsters. Starting from the 7th day after birth (defined as day 0 of lactation) of female and male Prkdc gene knockout Chinese hamster pups (n=6) and female and male WT Chinese hamster pups (n=6), the pups were weighed between 7:00 and 8:00 a.m. every day and weighed every two days until the end of lactation on the 23rd day. Growth curves were drawn to intuitively show the growth trend of Prkdc gene knockout Chinese hamsters during lactation. The results showed that the growth curves of both male and female Prkdc gene knockout Chinese hamsters were not significantly different from those of WT ( Figure 10 ).

[0185] The appearance of 10-week-old Prkdc gene knockout Chinese groundhogs (n=6) and WT Chinese groundhogs (n=6) was observed. The results showed that there were no significant differences in hair, skin, body length, and body width. Figure 11 ).

[0186] Example 11 Routine blood count of Prkdc gene knockout Chinese hamster

[0187] Species such as SCID mice lack T and B lymphocytes, which are also lacking in their peripheral blood. To analyze the content of peripheral blood mononuclear cells in Prkdc gene knockout Chinese hamsters, peripheral blood was collected from 12-week-old Prkdc gene knockout Chinese hamsters (n=6) and WT Chinese hamsters (n=6) by orbital blood sampling. Routine blood tests were performed on the peripheral blood of Prkdc gene knockout Chinese hamsters using a fully automatic hematology analyzer, and it was found that the white blood cell count, lymphocyte, neutrophil, monocyte, eosinophil, and basophil percentages were significantly lower than those of WT (Table 17).

[0188] Table 17 Blood routine of Prkdc gene knockout Chinese hamsters

[0189] index WT (n=6) PrkdcKO (n=6) P value <![CDATA[WBC(×10 9 / L)]]> 2.467±0.220 0.938±0.077 <0.001 <![CDATA[RBC(×10 12 / L)]]> 8.318±0.370 8.286±0.234 0.863 HCT (%) 11.583±0.412 11.567±0.175 0.929 MCV(fL) 14.150±0.217 14.017±0.172 0.265 MCH(pg) 17.833±0.403 17.917±0.386 0.722 MCHC (g / L) 1277.833±23.928 1282.333±25.065 0.757 CV (%) 15.183±0.231 15.150±0.187 0.789 <![CDATA[PLT(×10 9 / L)]]> 388.667±185.861 311.000±24.731 0.334 MPV(fL) 1.507±0.170 1.516±0.116 0.908 HGB (g / L) 148.500±3.619 148.333±2.658 0.929 NE%(%) 17.212±2.780 49.388±3.070 <0.001 LY%(%) 65.005±2.324 8.401±1.076 <0.001 MO% (%) 9.747±0.413 23.347±2.807 <0.001 EO% (%) 6.925±1.592 15.318±0.696 <0.001 BA% (%) 1.111±0.059 3.545±0.899 <0.001 <![CDATA[NE(×10 9 / L)]]> 0.430±0.096 0.464±0.059 0.476 <![CDATA[LY(×10 9 / L)]]> 1.600±0.110 0.079±0.011 <0.001 <![CDATA[MO(×10 9 / L)]]> 0.240±0.022 0.240±0.022 0.099 <![CDATA[EO(×10 9 / L)]]> 0.169±0.037 0.169±0.037 0.142 <![CDATA[BA(×10 9 / L)]]> 0.027±0.002 0.027±0.002 0.171

[0190] Note: WBC: white blood cell; RBC: red blood cell; HCT: hematocrit; MCV: mean corpuscular volume; MCH: mean corpuscular hemoglobin; MCHC: mean corpuscular hemoglobin concentration; CV: coefficient of variation; PLT: platelet; MPV: mean platelet volume; HGB: hemoglobin; NE%: neutrophil percentage; LYM%: lymphocyte percentage; MO%: monocyte percentage; EO%: eosinophil percentage; BA%: basophil percentage; NE: neutrophil count; LYM: lymphocyte count; MO: monocyte count; EO: eosinophil count; BA: basophil count.

[0191] Example 12 H&E staining of Prkdc gene knockout Chinese hamsters

[0192] Existing knockout species such as Prkdc gene knockout mice and rats do not have obvious organ pathological changes. In order to better evaluate whether Prkdc gene knockout Chinese hamsters have pathological changes in major organs, the present invention took the main organs of Prkdc gene knockout Chinese hamsters for hematoxylin and eosin (H&E) staining and compared them with WT Chinese hamsters. The specific steps are as follows:

[0193] (1) The procedures for tissue sampling, fixation, dehydration, transparency, wax immersion, paraffin embedding, sectioning, spreading, slicing, slicing, and dewaxing are consistent with the relevant steps (1) to (8) of immunohistochemical staining (Example 8);

[0194] (2) Hematoxylin staining for 2-5 minutes → washing with tap water for a while → hydrochloric acid-ethanol differentiation for a while → blueing with dilute ammonia water for 1 minute → washing with tap water for a while → 95% ethanol for 30 seconds → eosin counterstaining for 50 seconds → washing with tap water for a while (the dewaxing and staining time can be slightly adjusted according to actual conditions);

[0195] (3) 80% alcohol for 2 min → 90% alcohol for 2 min → 95% alcohol I and II for 2 min each → 100% alcohol I and II for 2 min each → xylene I and II for 10 min each;

[0196] (4) Add an appropriate amount of neutral gum to the slide, and slowly lower the cover slip from one side to complete the sealing process. Avoid generating bubbles during the sealing process. After sealing, place the slide in a fume hood to dry.

[0197] H&E staining was performed on the main organs (heart, liver, spleen, lung, kidney, and thymus) of the Prkdc gene knockout Chinese hamster to analyze whether there were pathological changes in the main organs after Prkdc gene knockout. The results showed that there were no obvious changes in the heart, liver, spleen, lung, and kidney of the Chinese hamster after Prkdc gene knockout. The thymus parenchyma was atrophic and showed vacuolar changes, and the number of lymphocytes was significantly reduced ( Figure 12 ).

[0198] The embodiments described above are merely descriptions of preferred embodiments of the present invention and are not intended to limit the scope of the present invention. Without departing from the spirit of the present invention, various modifications and improvements made to the technical solutions of the present invention by persons skilled in the art should fall within the scope of protection defined by the claims of the present invention.

Claims

1. A sgRNA for editing the Prkdc gene, characterized in that The nucleotide sequence of the sgRNA is shown in any one of SEQ ID NO.2-SEQ ID NO.

5.

2. Use of the sgRNA according to claim 1 in preparing a product for knocking out the Chinese hamster Prkdc gene.

3. The use according to claim 2, characterized in that The product includes a reagent or a kit.

4. A product for knocking out the Prkdc gene in Chinese hamsters, characterized in that: The product comprises the sgRNA of claim 1.

5. The product according to claim 4, characterized in that The product includes a reagent or a kit.

6. Use of the sgRNA according to claim 1 or the product according to claim 4 or 5 in constructing a Prkdc gene knockout Chinese hamster animal model.

7. A method for constructing a Prkdc gene knockout Chinese hamster animal model, characterized in that: The following steps are involved: After microinjecting the injection solution into the fertilized egg, the resulting fertilized egg is transplanted into a surrogate mother mouse to obtain offspring, identify the genotype, and obtain F0 generation positive Chinese hamsters; the injection solution comprises Cas9 mRNA and the sgRNA according to claim 1; mating the F0 generation positive Chinese hamster with a wild-type Chinese hamster to obtain an F1 generation Chinese hamster, identifying the genotype, and obtaining an F1 generation heterozygous Chinese hamster; The male and female F1 generation heterozygous Chinese hamsters are mated to obtain F2 generation Chinese hamsters, and the genotypes are identified to obtain F2 generation homozygous Chinese hamsters, thereby obtaining the Prkdc gene knockout Chinese hamster animal model.

8. The construction method according to claim 7, characterized in that: In the injection solution, the mass ratio of the sgRNA to the Cas9 mRNA is 1:

2.

9. The construction method according to claim 7, characterized in that: The dosage of the injection is 1 pL per tablet.

10. Use of the Prkdc gene knockout Chinese hamster animal model obtained by the construction method according to any one of claims 7 to 9 in studying the pathogenesis of immunodeficiency and / or tumor diseases.